Cardiovascular disease (CVD) risk factors and health behaviors following cisplatin-based chemotherapy (CHEM): A multi-institutional study of testicular cancer survivors (TCS).

Authors

Mohammad Abu Zaid

Mohammad Issam Abu Zaid

Indiana University School of Medicine, Indianapolis, IN

Mohammad Issam Abu Zaid , Chunkit Fung , AnnaLynn Williams , Howard D. Sesso , Sarah L Kerns , Darren R. Feldman , Robert James Hamilton , David J. Vaughn , Clair Beard , Hai Liu , Sophie D. Fossa , Lawrence H. Einhorn , Lois B. Travis

Organizations

Indiana University School of Medicine, Indianapolis, IN, Wilmot Cancer Center, Rochester, NY, University of Rochester School of Medicine and Dentistry, Rochester, NY, Division of Preventive Medicine, Harvard Medical School, Boston, MA, University of Rochester Medical Center, Rochester, NY, Memorial Sloan Kettering Cancer Center, New York, NY, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA, Oslo University Hospital, University of Oslo, Oslo, Norway, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Research Funding

No funding sources reported

Background: TCS are at increased risk of CVD, but few clinical studies have comprehensively evaluated CVD risk factors through physical exams, lipid panels, and health behaviors in North American patients. Methods: Eligible TCS were < 50 y at diagnosis and treated with only first line CHEM. TCS underwent physical exams, had fasting lipid panels, and completed questionnaires regarding co-morbidities and health behaviors. Age, race, and educational status-matched controls (1:1) were chosen from the general population using the 2011-2012 National Health and Nutrition Examination Survey. Odds ratios (OR) of outcomes among TCS versus matched controls were estimated using logistic regression models. Results: We evaluated 680 consecutively enrolled TCS. Median age at diagnosis was 31 y (range, 15-49) and at clinical evaluation 38 y (range, 19-68). Median time since CHEM was 4.3 y (range, 1-30). Compared to normative controls, TCS were more likely to be overweight (OR = 1.65; 95% CI 1.26-2.16), have total cholesterol ≥ 240 mg/dL (OR = 2.19; 95% CI 1.12-4.28) and LDL ≥ 160 mg/dL (OR = 3.05; 95% CI 1.03-9.00), and report alcohol use > 2 days/week (OR = 2.13; 95% CI 1.64-2.77). In contrast, they were more likely to have a waist circumference < 40 inches (OR = 1.32; 95% CI 1.04-1.66); engage in vigorous (OR = 2.64; 95% CI 2.11-3.29) or moderate (OR = 1.62; 95% CI 1.30-2.03) physical activity, and not smoke (OR = 2.95; 95% CI 2.14-4.08). TCS were about 3 times more likely overall to report excellent, very good, or good health compared to controls (P < 0.05). No significant differences were found comparing HDL, triglycerides, or self-reported hypertension (P > 0.05). Conclusions: Although North American TCS appear more likely to exercise and abstain from smoking compared to normative controls, a greater proportion are overweight and have higher fasting total cholesterol and LDL levels. Health care providers should screen TCS for CVD risk factors, and encourage practices consistent with a healthy lifestyle. Future research should elucidate mechanisms of increased CVD risk and ultimately develop customized prevention and intervention strategies.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 Cancer Survivorship Symposium

Session Type

Poster Session

Session Title

Poster Session B

Track

Care Coordination and Financial Implications,Communication,Late- and Long-term Effects/Comorbidities,Health Promotion,Psychosocial Issues,Recurrence and Secondary Malignancies

Sub Track

Long-term Complications/Sequelae of Treatment (Noncancer)

Citation

J Clin Oncol 34, 2016 (suppl 3S; abstr 129)

DOI

10.1200/jco.2016.34.3_suppl.129

Abstract #

129

Poster Bd #

D5

Abstract Disclosures